Sesamin Suppresses Ovarian Cancer Progression via Modulation of Wnt/β-Catenin and Associated Oncogenic Pathways.

Authors

Heera Maheswari Jayaveeran, Ponnulakshmi Rajagopal, Manju Parthiban, Selvaraj Jayaraman, Sureka Varalakshmi V, Krithika Chandrasekaran

Published in

Asian Pacific journal of cancer prevention : APJCP. Volume 27. Issue 6. Pages 2149-2155. Jun 01, 2026. Epub Jun 01, 2026.

Abstract

The current research aimed to explore the molecular pathway of sesamin in controlling the Wnt/β-catenin signaling pathway and associated oncogenic regulators in ovarian cancer cells.
Molecular docking was conducted to assess sesamin's binding activity toward major signaling proteins (Wnt, β-catenin, GSK3β, TGF-β). Functional confirmation was performed using quantitative PCR (qPCR) to quantify gene expression following a 48-hour treatment of ovarian cancer cells with sesamin.
Docking simulations revealed strong binding affinities, particularly with Wnt (-9.19 kcal/mol), supported by hydrogen bond interactions. qPCR results showed significant downregulation of Wnt (50%), TGF-β (40%), GSK3β (25%), and β-catenin transcripts compared to the control (p < 0.001).
Sesamin potently inhibits several oncogenic regulators within the Wnt/β-catenin pathway, positioning it as a potential multi-target natural therapeutic for ovarian cancer. These findings support sesamin as a promising candidate for further preclinical and clinical investigation, particularly as an adjuvant therapy to overcome drug resistance and limit tumor progression.

PMID:
42345162
Bibliographic data and abstract were imported from PubMed on 25 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.